The Bcr-Abl tyrosine kinase inhibitor imatinib and promising new agents against Philadelphia chromosome-positive leukemias (Q36967858)

17 August 2017

1 reference

title

The Bcr-Abl tyrosine kinase inhibitor imatinib and promising new agents against Philadelphia chromosome-positive leukemias (English)

1 reference

17 August 2017

1 reference

Philadelphia chromosome

1 reference

object named as

Philadelphia chromosome

2 August 2024

Taira Maekawa

1 reference

17 August 2017

Eishi Ashihara

series ordinal

1 reference

17 August 2017

Shinya Kimura

series ordinal

1 reference

17 August 2017

publication date

22 October 2007

1 reference

International Journal of Clinical Oncology

17 August 2017

published in

1 reference

17 August 2017

1 reference

17 August 2017

1 reference

17 August 2017

page(s)

327-340

1 reference

Chronic myelogenous leukemia: biology and therapy

17 August 2017

cites work

1 reference

https://api.crossref.org/works/10.1007%2FS10147-007-0699-1

Interaction of tyrosine kinase inhibitors with the human multidrug transporter proteins, MDR1 and MRP1.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10147-007-0699-1

Cytogenetic and molecular mechanisms of resistance to imatinib

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10147-007-0699-1

New insights into the pathophysiology of chronic myeloid leukemia and imatinib resistance

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10147-007-0699-1

Primitive, quiescent and difficult to kill: the role of non-proliferating stem cells in chronic myeloid leukemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10147-007-0699-1

Busulfan versus hydroxyurea in long-term therapy of chronic myelogenous leukemia

21 January 2018

1 reference

12 December 2020

Dasatinib in imatinib-resistant Philadelphia chromosome-positive leukemias

1 reference

12 December 2020

Activation of Src kinases p53/56lyn and p59hck by p210bcr/abl in myeloid cells

1 reference

12 December 2020

Suppression of Philadelphia1 leukemia cell growth in mice by BCR-ABL antisense oligodeoxynucleotide

1 reference

12 December 2020

BCR-ABL independence and LYN kinase overexpression in chronic myelogenous leukemia cells selected for resistance to STI571.

1 reference

12 December 2020

Induction of chronic myelogenous leukemia in mice by the P210bcr/abl gene of the Philadelphia chromosome

1 reference

12 December 2020

Inhibition of drug-resistant mutants of ABL, KIT, and EGF receptor kinases

1 reference

12 December 2020

Discovery of N-(2-chloro-6-methyl- phenyl)-2-(6-(4-(2-hydroxyethyl)- piperazin-1-yl)-2-methylpyrimidin-4- ylamino)thiazole-5-carboxamide (BMS-354825), a dual Src/Abl kinase inhibitor with potent antitumor activity in preclinical assays.

1 reference

12 December 2020

Imatinib increases the intracellular concentration of nilotinib, which may explain the observed synergy between these drugs

1 reference

12 December 2020

Characterization of AMN107, a selective inhibitor of native and mutant Bcr-Abl.

1 reference

12 December 2020

In vitro activity of Bcr-Abl inhibitors AMN107 and BMS-354825 against clinically relevant imatinib-resistant Abl kinase domain mutants

1 reference

12 December 2020

Inhibition of wild-type and mutant Bcr-Abl by AP23464, a potent ATP-based oncogenic protein kinase inhibitor: implications for CML.

1 reference

12 December 2020

Imatinib therapy in chronic myelogenous leukemia: strategies to avoid and overcome resistance

1 reference

12 December 2020

Bone marrow transplantation for chronic myeloid leukaemia

1 reference

12 December 2020

A Bcr/Abl-independent, Lyn-dependent form of imatinib mesylate (STI-571) resistance is associated with altered expression of Bcl-2.

1 reference

12 December 2020

Imatinib mesylate resistance through BCR-ABL independence in chronic myelogenous leukemia

1 reference

12 December 2020

The structure of Dasatinib (BMS-354825) bound to activated ABL kinase domain elucidates its inhibitory activity against imatinib-resistant ABL mutants

1 reference

12 December 2020

Src family tyrosine kinases and growth factor signaling

1 reference

12 December 2020

Tumour stem cells and drug resistance

1 reference

12 December 2020

Important therapeutic targets in chronic myelogenous leukemia

1 reference

12 December 2020

A tyrosine kinase created by fusion of the PDGFRA and FIP1L1 genes as a therapeutic target of imatinib in idiopathic hypereosinophilic syndrome

1 reference

12 December 2020

Tyrosine kinases as targets for cancer therapy

1 reference

12 December 2020

SKI-606, a Src/Abl inhibitor with in vivo activity in colon tumor xenograft models

1 reference

12 December 2020

Drug resistance in cancer: principles of emergence and prevention

1 reference

12 December 2020

VX-680, a potent and selective small-molecule inhibitor of the Aurora kinases, suppresses tumor growth in vivo

1 reference

12 December 2020

Structural mechanism for STI-571 inhibition of abelson tyrosine kinase

1 reference

12 December 2020

Establishment and molecular characterization of a novel leukemic cell line with Philadelphia chromosome expressing p230 BCR/ABL fusion protein

1 reference

12 December 2020

The third-generation bisphosphonate zoledronate synergistically augments the anti-Ph+ leukemia activity of imatinib mesylate

1 reference

12 December 2020

Short interfering RNA (siRNA) targeting the Lyn kinase induces apoptosis in primary, and drug-resistant, BCR-ABL1(+) leukemia cells

1 reference

12 December 2020

Structure of the kinase domain of an imatinib-resistant Abl mutant in complex with the Aurora kinase inhibitor VX-680.

1 reference

12 December 2020

The development of imatinib as a therapeutic agent for chronic myeloid leukemia

1 reference

12 December 2020

Tyrosine kinase activity and transformation potency of bcr-abl oncogene products.

1 reference

12 December 2020

Overriding imatinib resistance with a novel ABL kinase inhibitor

1 reference

12 December 2020

Acute leukaemia in bcr/abl transgenic mice

1 reference

12 December 2020

Combined Abl inhibitor therapy for minimizing drug resistance in chronic myeloid leukemia: Src/Abl inhibitors are compatible with imatinib

1 reference

12 December 2020

Autoinhibition of Bcr-Abl through its SH3 domain

1 reference

12 December 2020

Chronic myeloid leukemia

1 reference

12 December 2020

Nilotinib exerts equipotent antiproliferative effects to imatinib and does not induce apoptosis in CD34+ CML cells

1 reference

12 December 2020

Molecular mechanisms of transformation by the BCR-ABL oncogene

1 reference

12 December 2020

A comparison of normal and leukemic stem cell biology in Chronic Myeloid Leukemia.

1 reference

12 December 2020

Design and synthesis of 3-substituted benzamide derivatives as Bcr-Abl kinase inhibitors

1 reference

12 December 2020

In vivo antiproliferative effect of NS-187, a dual Bcr-Abl/Lyn tyrosine kinase inhibitor, on leukemic cells harbouring Abl kinase domain mutations

1 reference

12 December 2020

Abl inhibitor BMS354825 binding mode in Abelson kinase revealed by molecular docking studies

1 reference

12 December 2020

Activity of dual SRC-ABL inhibitors highlights the role of BCR/ABL kinase dynamics in drug resistance

1 reference

12 December 2020

Chronic myeloid leukemia--past, present, and future

1 reference

12 December 2020

Efficient and rapid induction of a chronic myelogenous leukemia-like myeloproliferative disease in mice receiving P210 bcr/abl-transduced bone marrow

1 reference

12 December 2020

Second-line treatment with dasatinib in patients resistant to imatinib can select novel inhibitor-specific BCR-ABL mutants in Ph+ ALL

1 reference

12 December 2020

SKI-606, a 4-anilino-3-quinolinecarbonitrile dual inhibitor of Src and Abl kinases, is a potent antiproliferative agent against chronic myelogenous leukemia cells in culture and causes regression of K562 xenografts in nude mice

1 reference

12 December 2020

Efficacy and safety of a specific inhibitor of the BCR-ABL tyrosine kinase in chronic myeloid leukemia

1 reference

12 December 2020

Results of triple therapy with interferon-alpha, cytarabine, and homoharringtonine, and the impact of adding imatinib to the treatment sequence in patients with Philadelphia chromosome-positive chronic myelogenous leukemia in early chronic phase

1 reference

12 December 2020

MK-0457, a novel kinase inhibitor, is active in patients with chronic myeloid leukemia or acute lymphocytic leukemia with the T315I BCR-ABL mutation

1 reference

12 December 2020

Prolonged survival in chronic myelogenous leukemia after cytogenetic response to interferon-alpha therapy. The Leukemia Service

1 reference

12 December 2020

Crystal structures of the kinase domain of c-Abl in complex with the small molecule inhibitors PD173955 and imatinib (STI-571)

1 reference

12 December 2020

Dynamics of chronic myeloid leukaemia.

1 reference

12 December 2020

Signal transduction inhibition: results from phase I clinical trials in chronic myeloid leukemia

1 reference

12 December 2020

Fusion of PDGF receptor beta to a novel ets-like gene, tel, in chronic myelomonocytic leukemia with t(5;12) chromosomal translocation

1 reference

12 December 2020

Chronic Myeloid Leukemia — Advances in Biology and New Approaches to Treatment

1 reference

12 December 2020

A non-ATP-competitive inhibitor of BCR-ABL overrides imatinib resistance

1 reference

12 December 2020

Isolation of a highly quiescent subpopulation of primitive leukemic cells in chronic myeloid leukemia.

1 reference

12 December 2020

Comparison of imatinib mesylate, dasatinib (BMS-354825), and nilotinib (AMN107) in an N-ethyl-N-nitrosourea (ENU)-based mutagenesis screen: high efficacy of drug combinations

1 reference

12 December 2020

The molecular genetics of Philadelphia chromosome-positive leukemias

1 reference

12 December 2020

BIRB-796 is not an effective ABL(T315I) inhibitor

1 reference

12 December 2020

Requirement of Src kinases Lyn, Hck and Fgr for BCR-ABL1-induced B-lymphoblastic leukemia but not chronic myeloid leukemia

1 reference

12 December 2020

The Src family kinase Hck couples BCR/ABL to STAT5 activation in myeloid leukemia cells.

1 reference

12 December 2020

Chronic imatinib mesylate exposure leads to reduced intracellular drug accumulation by induction of the ABCG2 (BCRP) and ABCB1 (MDR1) drug transport pumps

1 reference

12 December 2020

Active transport of imatinib into and out of cells: implications for drug resistance

1 reference

12 December 2020

Anti-proliferative effect of the abl tyrosine kinase inhibitor STI571 on the P-glycoprotein positive K562/ADM cell line

1 reference

12 December 2020

Mechanisms and implications of imatinib resistance mutations in BCR-ABL.

1 reference

12 December 2020

Denaturing-HPLC-based assay for detection of ABL mutations in chronic myeloid leukemia patients resistant to Imatinib

1 reference

12 December 2020

The diversity of BCR-ABL fusion proteins and their relationship to leukemia phenotype

1 reference

12 December 2020

The tyrosine kinase inhibitor CGP57148B selectively inhibits the growth of BCR-ABL-positive cells

1 reference

12 December 2020

c-Abl regulation: a tail of two lipids

1 reference

12 December 2020

Inhibition of the ABL kinase activity blocks the proliferation of BCR/ABL+ leukemic cells and induces apoptosis.

1 reference

12 December 2020

After 30 years of laboratory work, a quick approval for STI571.

1 reference

12 December 2020

High-dose imatinib mesylate therapy in newly diagnosed Philadelphia chromosome-positive chronic phase chronic myeloid leukemia

1 reference

12 December 2020

The interaction of the Bcr-Abl tyrosine kinase with the Src kinase Hck is mediated by multiple binding domains

1 reference

12 December 2020

Role of alpha1 acid glycoprotein in the in vivo resistance of human BCR-ABL(+) leukemic cells to the abl inhibitor STI571

1 reference

12 December 2020

Dasatinib (BMS-354825) is active in Philadelphia chromosome-positive chronic myelogenous leukemia after imatinib and nilotinib (AMN107) therapy failure

1 reference

12 December 2020

Inhibition of the Abl protein-tyrosine kinase in vitro and in vivo by a 2-phenylaminopyrimidine derivative.

1 reference

12 December 2020

INNO-406, a novel BCR-ABL/Lyn dual tyrosine kinase inhibitor, suppresses the growth of Ph+ leukemia cells in the central nervous system, and cyclosporine A augments its in vivo activity.

1 reference

12 December 2020

NS-187, a potent and selective dual Bcr-Abl/Lyn tyrosine kinase inhibitor, is a novel agent for imatinib-resistant leukemia

1 reference

12 December 2020

Imatinib mesylate (STI571) inhibits growth of primitive malignant progenitors in chronic myelogenous leukemia through reversal of abnormally increased proliferation

1 reference

12 December 2020

Letter: A new consistent chromosomal abnormality in chronic myelogenous leukaemia identified by quinacrine fluorescence and Giemsa staining

1 reference

12 December 2020

Clinical resistance to STI-571 cancer therapy caused by BCR-ABL gene mutation or amplification

1 reference

12 December 2020

Dasatinib induces significant hematologic and cytogenetic responses in patients with imatinib-resistant or -intolerant chronic myeloid leukemia in accelerated phase

1 reference

12 December 2020

ABL mutations in late chronic phase chronic myeloid leukemia patients with up-front cytogenetic resistance to imatinib are associated with a greater likelihood of progression to blast crisis and shorter survival: a study by the GIMEMA Working Party o

1 reference

12 December 2020

Ph(+) acute lymphoblastic leukemia resistant to the tyrosine kinase inhibitor STI571 has a unique BCR-ABL gene mutation

1 reference

12 December 2020

Detection of BCR-ABL mutations in patients with CML treated with imatinib is virtually always accompanied by clinical resistance, and mutations in the ATP phosphate-binding loop (P-loop) are associated with a poor prognosis

1 reference

12 December 2020

1 reference

12 December 2020

Multiple BCR-ABL kinase domain mutations confer polyclonal resistance to the tyrosine kinase inhibitor imatinib (STI571) in chronic phase and blast crisis chronic myeloid leukemia

1 reference

12 December 2020

Nilotinib in imatinib-resistant CML and Philadelphia chromosome-positive ALL

1 reference

12 December 2020

Evolving concepts in the management of chronic myeloid leukemia: recommendations from an expert panel on behalf of the European LeukemiaNet

1 reference

12 December 2020

Critical role for Gab2 in transformation by BCR/ABL

1 reference

12 December 2020

Localization of the c-abl oncogene adjacent to a translocation break point in chronic myelocytic leukaemia

1 reference

12 December 2020

CHIC2 deletion, a surrogate for FIP1L1-PDGFRA fusion, occurs in systemic mastocytosis associated with eosinophilia and predicts response to imatinib mesylate therapy

1 reference

12 December 2020

Sequence specificity on the growth suppression and induction of apoptosis of chronic myeloid leukemia cells by BCR‐ABL anti‐sense oligodeoxynucleoside phosphorothioates

1 reference

12 December 2020

Five-year follow-up of patients receiving imatinib for chronic myeloid leukemia

1 reference

12 December 2020

Dasatinib (BMS-354825) targets an earlier progenitor population than imatinib in primary CML but does not eliminate the quiescent fraction

1 reference

12 December 2020

Imatinib compared with interferon and low-dose cytarabine for newly diagnosed chronic-phase chronic myeloid leukemia

1 reference

12 December 2020

Beneficial effects of combining nilotinib and imatinib in preclinical models of BCR-ABL+ leukemias

1 reference

12 December 2020

Molecular mechanisms of resistance to imatinib in Philadelphia-chromosome-positive leukaemias.

1 reference

12 December 2020

Persistence of malignant hematopoietic progenitors in chronic myelogenous leukemia patients in complete cytogenetic remission following imatinib mesylate treatment

1 reference

12 December 2020

Comparative analysis of two clinically active BCR-ABL kinase inhibitors reveals the role of conformation-specific binding in resistance

1 reference

12 December 2020

Imatinib (STI571) resistance in chronic myelogenous leukemia: molecular basis of the underlying mechanisms and potential strategies for treatment

1 reference

12 December 2020

Effects of a selective inhibitor of the Abl tyrosine kinase on the growth of Bcr-Abl positive cells

1 reference

12 December 2020

Result of high-dose imatinib mesylate in patients with Philadelphia chromosome-positive chronic myeloid leukemia after failure of interferon-alpha

1 reference

12 December 2020

Imatinib induces hematologic and cytogenetic responses in patients with chronic myelogenous leukemia in myeloid blast crisis: results of a phase II study.

1 reference

12 December 2020

Primitive, quiescent, Philadelphia-positive stem cells from patients with chronic myeloid leukemia are insensitive to STI571 in vitro

1 reference

12 December 2020

A new fused transcript in Philadelphia chromosome positive acute lymphocytic leukaemia

1 reference

12 December 2020

Relation between resistance of Philadelphia-chromosome-positive acute lymphoblastic leukaemia to the tyrosine kinase inhibitor STI571 and gene-expression profiles: a gene-expression study

1 reference

12 December 2020

AMN107, a novel aminopyrimidine inhibitor of Bcr-Abl, has in vitro activity against imatinib-resistant chronic myeloid leukemia

1 reference

12 December 2020

10.1007/S10147-007-0699-1

Identifiers

DOI

1 reference

17 August 2017

1 reference